NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal D… (NCT07810023, ketamine)
This non-randomised, open-label, single-group pilot study (n=8) will evaluate the feasibility and acceptability of a single intramuscular dose of ketamine 35mg/70kg for the acute reduction of suicidal distress in adul...
Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease
This rat study found that a single psilocybin dose (2.5 mg/kg) improved spatial memory and learning in a chemically induced model of Alzheimer's-like pathology. The behavioural improvements were not accompanied by con...
Longevity Medicine and Psychedelics w/ Dr. Jordanna Quinn
Dr. Jordanna Quinn is a board-certified physician and founder of Kore Regenerative Medicine. One of the early physicians in longevity medicine to focus on the connection between cellular and mental health, she treats ...
Psychedelics and anesthetics create mirror image patterns in the brain
For something so familiar to human experience, consciousness is still a mystery. Each day, people cycle through wakefulness and sleep, from a higher level of consciousness to a lower one. What's more, some people alte...
Indigenous Medicines Are Inseparable From Territory
Ayahuasca can't be separated from the land, community, and people who protect it. [...] Read More... The post Indigenous Medicines Are Inseparable From Territory appeared first on DoubleBlind Mag.
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+…
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
LONDON & NEW YORK, September 09, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
In mice, 4-AcO-DMT reduced freezing triggered by a visual threat by activating prelimbic cortex CaMKIIα neurons through 5-HT2A receptors.
4-AcO-DMT reduced looming-induced freezing in a visual-threat model in mice, independently of visual function and β-arrestin 2 signalling. The anti-fear response involved a prelimbic cortex CaMKIIα to mediodorsal thal...
The FDA is considering new methods to evaluate psychedelic-assisted therapies for mental health conditions, including changes to study design, administration and long-term monitoring.
The FDA is signalling openness to novel approaches for assessing psychedelics including psilocybin, MDMA, LSD, DMT and ketamine. Potential changes could address study design, administration methods and long-term monit...
Compass Pathways reported 52-week open-label COMP005 data showing an additional COMP360 25 mg dose extended benefit to one year in treatment-resistant depression.
In Phase 3 COMP005, participants randomised to 25 mg who received another dose had an average 13-point MADRS reduction from baseline at Week 52. Among all Part C recipients, 40% to 45% were responders and about 30% we...
Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care
This observational cohort study (n=115) examined smoking cessation outcomes in people classified as either dependence-predominant or affective-predominant, and found that psilocybin-assisted care was associated with g...
Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care
This observational cohort study (n=115) examined smoking cessation outcomes in people classified as either dependence-predominant or affective-predominant, and found that psilocybin-assisted care was associated with g...
Huachuma, the Andean psychedelic cactus, is drawing Western seekers and raising ethical questions
For at least two decades, thousands of Americans have been going to Peru, Ecuador, Colombia and Brazil to look for ayahuasca, a psychoactive brew traditionally used in sacred ceremonies in South America. Ayahuasca con...
Huachuma, the Andean psychedelic cactus, is drawing Western seekers and raising ethical questions
Huachuma, the Andean cactus better known as San Pedro, contains mescaline, a psychoactive compound that alters perception and mood.
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
NEW YORK, September 08, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to…